New frontiers in precision medicine for Sjogren's syndrome. (1st February 2021)

• Record Type: Journal Article
• Authors: Chatzis, Loukas; Vlachoyiannopoulos, Panayiotis G; Tzioufas, Athanasios G; Goules, Andreas V
• Is Part Of: Expert review of clinical immunology. Volume 17:Number 2(2021)
• Page Start: 127
• Page End: 141
• Publication Date: 2021-02-01
• Subjects: Sjogren's syndrome -- biomarkers -- precision medicine -- lymphoma; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2021.1879641
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction : Sjögren's syndrome is a unique systemic autoimmune disease, placed in the center of systemic autoimmunity and at the crossroads of autoimmunity and lymphoproliferation. The diverse clinical picture of the disease, the inefficacy of current biologic treatments, and the co-existence with lymphoma conferring to the patients' morbidity and mortality force the scientific community to review disease pathogenesis and reveal the major implicated cellular and molecular elements. Areas covered : Biomarkers for early diagnosis, prediction, stratification, monitoring, and targeted treatments can serve as a tool to interlink and switch from the clinical phenotyping of the disease into a more sophisticated classification based on the underlying critical molecular pathways and endotypes. Such a transition may define the establishment of the so-called precision medicine era in which patients' management will be based on grouping according to pathogenetically related biomarkers. In the current work, literature on Sjogren's syndrome covering several research fields including clinical, translational, and basic research has been reviewed. Expert opinion : The perspectives of clinical and translational research are anticipated to define phenotypic clustering of high-risk pSS patients and link the clinical picture of the disease with fundamental molecular mechanisms and molecules implicated in pathogenesis.